BCL2L1 and Familial prostate cancer: MiRNA-361 is reported to regulate epithelial to mesenchymal transition through the extracellular signaling-related kinases (ERK), signaled by RAS(68), and acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6 (STAT6), a pro-apoptotic signaler to BCL-xL (69).